^
Association details:
Biomarker:No biomarker
Cancer:Nasopharyngeal Carcinoma
Drug:Tevimbra (tislelizumab-jsgr) (PD1 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
Title:

Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline

Published date:
12/15/2022
Excerpt:
Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers....Recommendation 4.1….Toripalimab, camrelizumab, or tislelizumab, with gemcitabine and cisplatin, should be offered as first-line treatment for patients with recurrent or metastatic nasopharyngeal cancer
Secondary therapy:
cisplatin + gemcitabine
DOI:
10.1200/JCO.22.02328
Evidence Level:
Sensitive: B - Late Trials
Title:

Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)

Published date:
05/18/2023
Excerpt:
PFS after next line of treatment and overall survival showed favorable trends for tislelizumab-chemotherapy versus placebo-chemotherapy....Our results support that tislelizumab-chemotherapy should be considered as first-line treatment for R/M NPC, and GEP and activated DC signature results may help identify patients who might benefit most from immunochemotherapy treatment.
DOI:
10.1016/j.ccell.2023.04.014
Trial ID: